ArticleJournal of molecular histology2025
Salvianolic acid A reduces lipotoxicity injury of cardiomyocytes by orchestrating oxidative stress and inflammation via Akt/Nrf2/NF-κB axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac lipid metabolism is easily affected by the surrounding environment, which is involved in the development of heart disease. Salvianolic acid A (SAA) is a phenolic acid with good therapeutic effects on cardiovascular disease. However, the mechanism of how SAA coordinates the crosstalk of oxidative stress and inflammation to reduce the lipid induced-cardiomyocyte injury has not been reported. This study aimed to explore how SAA alleviates lipotoxicity of cardiomyocytes by regulating the crosstalk of oxidative stress and inflammation.
methodsPalmitate (PA)-injured H9c2 model was used to mimic lipotoxic myocardial injury. Cardiomyocyte viability and damage was detected by CCK-8 and LDH assay, respectively. Apoptosis was evaluated by TUNEL staining. Intracellular lipid accumulation was detected by fluorescent lipid probe. Inflammation cytokines (IL-1β, TNF-α and IL-6) and oxidative stress levels (ROS, SOD and MDA) were examined as well. Meanwhile, levels of related proteins involved in Akt/Nrf2/NF-κB axis were determined by western blotting and immunofluorescent staining. Furthermore, Akt inhibitor (MK2206) and si-Nrf2 RNA were used to preliminarily confirm the mechanism of SAA on regulating oxidative stress and inflammation crosstalk.
resultsSAA memorably alleviated PA-injured H9c2 cardiomyocytes from apoptosis, oxidative stress and inflammation. SAA increased the levels of Akt and GSK-3β phosphorylation and nuclear translocation of Nrf2, while decreased the levels of NF-κB phosphorylation and nuclear translocation. Furthermore, the anti-apoptosis and anti-oxidation effects of SAA were restrained as a result of the MK2206 intervention, while the anti-inflammatory effects partially disappeared due to the silenced Nrf2.
conclusionSAA prevents PA-induced cardiotoxicity by orchestrating oxidative stress and inflammation via Akt/Nrf2/NF-κB axis.
Indexed as
Identifiers
41460302What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.